Enterprise Value
1.202B
Cash
144.9M
Avg Qtr Burn
-40.07M
Short % of Float
23.99%
Insider Ownership
8.59%
Institutional Own.
64.76%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
BRIUMVI (Ublituximab) (CD20) Details Multiple sclerosis | Approved Quarterly sales | |
TG-1701 (BTK inhibitor) Details Chronic lymphocytic leukemia, Cancer | Phase 1 Data readout | |
TG-1801 (anti-CD47/anti-CD19) Details Cancer, B-cell lymphoma, B-cell malignancies | Phase 1 Data readout | |
UKONIQ® (Umbralisib) (PI3K-delta & CK1-epsilon inhibitor) Details FL (Follicular Lymphoma) | Failed Discontinued | |
Umbralisib (PI3K-delta & CK1-epsilon inhibitor) + Ublituximab (CD20) Details R/R CLL (Relapsed/Refractory Chronic Lymphocytic Leukemia) | Failed Discontinued |